ENTRY       D09730                      Drug
NAME        Olaparib (JAN/USAN/INN);
            Lynparza (TN)
PRODUCT     LYNPARZA (AstraZeneca Pharmaceuticals LP)
FORMULA     C24H23FN4O3
EXACT_MASS  434.1754
MOL_WEIGHT  434.4628
CLASS       Antineoplastic
             DG02942  PARP inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01XK01
            Product: D09730<JP/US>
EFFICACY    Antineoplastic, PARP inhibitor
  DISEASE   Ovarian cancer [DS:H00027]
            Ovarian cancer (BRCA-mutated) [DS:H00027]
            Ovarian cancer (HRD-positive) [DS:H00027]
            Breast cancer (BRCA-mutated, HER2-negative) [DS:H00031]
            Pancreatic adenocarcinoma (BRCA-mutated) [DS:H00019]
            Prostate cancer, castration-resistant (HRR gene-mutated) [DS:H00024]
            Prostate cancer, castration-resistant (BRCA-mutated) [DS:H00024]
COMMENT     PARP inhibition in BRCA1 [HSA:672] [KO:K10605] and BRCA2 [HSA:675] [KO:K08775] -mutation
TARGET      PARP1 [HSA:142] [KO:K24070]
            PARP2 [HSA:10038] [KO:K10798]
  PATHWAY   hsa03410(10038+142)  Base excision repair
            hsa04064(142)  NF-kappa B signaling pathway
            hsa04210(10038+142)  Apoptosis
            hsa04217(142)  Necroptosis
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
OTHER_MAP   map04212  Longevity regulating pathway - worm
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
                 L01XK01 Olaparib
                  D09730  Olaparib (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Olaparib
                D09730  Olaparib (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09730  Olaparib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02942  PARP inhibitor
               D09730  Olaparib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               D09730  Olaparib
            Drug classes [BR:br08332]
             Antineoplastic
              DG02942  PARP inhibitor
               D09730  Olaparib
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Transferases (EC2)
               Pentosyltransferases
                PARP1
                 D09730  Olaparib (JAN/USAN/INN) &lt;JP/US&gt;
                PARP2
                 D09730  Olaparib (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09730
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09730
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09730
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09730
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D09730
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09730
DBLINKS     CAS: 763113-22-0
            PubChem: 124490470
            ChEBI: 83766
            PDB-CCD: 09L
            LigandBox: D09730
ATOM        32
            1   C8x C    14.9800  -23.2400
            2   C8x C    14.9800  -21.8400
            3   C8x C    16.1700  -21.1400
            4   C8y C    17.4300  -21.8400
            5   C8y C    17.4300  -23.2400
            6   C8x C    16.1700  -23.9400
            7   C8y C    18.6200  -21.1400
            8   N5x N    19.8100  -21.8400
            9   N4x N    19.8100  -23.2400
            10  C8y C    18.6200  -23.9400
            11  O5x O    18.6200  -25.3400
            12  C1b C    18.6200  -19.7400
            13  C8y C    19.8100  -19.0400
            14  C8x C    19.8100  -17.6400
            15  C8x C    21.0700  -16.9400
            16  C8y C    22.2600  -17.6400
            17  C8y C    22.2600  -19.0400
            18  C8x C    21.0700  -19.7400
            19  X   F    23.4500  -16.9400
            20  C5a C    23.4500  -19.7400
            21  N1y N    24.6400  -19.0400
            22  O5a O    23.4500  -21.1400
            23  C1x C    24.6400  -17.6400
            24  C1x C    25.9000  -16.9400
            25  N1y N    27.0900  -17.6400
            26  C1x C    27.0900  -19.0400
            27  C1x C    25.9000  -19.7400
            28  C5a C    28.2800  -16.9400
            29  C1y C    29.4700  -17.6400
            30  O5a O    28.2800  -15.5400
            31  C1x C    30.8700  -17.6400
            32  C1x C    30.1700  -18.8300
BOND        36
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 1
            11    5  10 1
            12   10  11 2
            13    7  12 1
            14   12  13 1
            15   13  14 2
            16   14  15 1
            17   15  16 2
            18   16  17 1
            19   17  18 2
            20   13  18 1
            21   16  19 1
            22   17  20 1
            23   20  21 1
            24   20  22 2
            25   21  23 1
            26   23  24 1
            27   24  25 1
            28   25  26 1
            29   26  27 1
            30   21  27 1
            31   25  28 1
            32   28  29 1
            33   28  30 2
            34   29  31 1
            35   31  32 1
            36   32  29 1
///
